



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)
C07K 16/40 (2006.01)

(21) International Application Number:

PCT/EP2015/076111

(22) International Filing Date:

9 November 2015 (09.11.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/077,486	10 November 2014 (10.11.2014)	US
62/147,329	14 April 2015 (14.04.2015)	US
62/188,999	6 July 2015 (06.07.2015)	US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **MINTER, Ralph**; MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **RUST, Steven**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **GUILLARD, Sandrine**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **JER-MUTUS, Lutz, U**; MedImmune Limited Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **HAY, Carl**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **SACHSENMEIER, Kris**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **SULT, Erin**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **HUANG, Qihui**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **PAVLIK, Peter**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **DAMS-CHRODER, Melissa**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **CHENG, Li**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **DIEDRICH, Gundo**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **RIOS-DORIA, Jonathan**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **HAM-**

MOND, Scott; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **HOLLINGSWORTH, Robert, E**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **DURHAM, Nicholas**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **LEOW, Ching, Ching**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **ANTONYSAMY, Mary**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **GEOGHEGAN, James**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **LU, Xiaojun**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US). **ROSENTHAL, Kim**; MedImmune, LLC One MedImmune Way, Gaithersburg, MD 20878 (US).

(74) Agent: **WINTER, Christopher**; MedImmune Limited Milstein Building, Cambridge Cambridgeshire Granta Park (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF

(57) Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

